Lonza is expanding its bioconjugation manufacturing capabilities at its Visp, Switzerland, site, combining upgraded mid-scale production capacity with a new large-scale facility to support antibody-drug conjugates (ADCs) and other bioconjugated medicines from clinical development through commercial manufacturing. The expansion includes two complementary investments designed to address growing demand as more ADCs and other bioconjugates advance through clinical trials toward commercialization. Lonza plans to upgrade existing mid-scale manufacturing suites with standardized single-use technology by 2027, while a new large-scale facility is expected to begin operations in 2028.

The mid-scale upgrades will provide 500-liter single-use manufacturing capacity within Lonza’s existing bioconjugation operations. Planned improvements include additional single-use equipment, chromatography capabilities, and parallel manufacturing capacity. These changes are intended to improve production scheduling, shorten changeover times between manufacturing campaigns, and accommodate a wider range of customer programs.

At the same site, Lonza is constructing a large-scale facility that will include three multiproduct manufacturing suites for both cytotoxic and non-cytotoxic products. The facility will incorporate stainless-steel and single-use technologies, with manufacturing capacity of up to 1,200 liters. Once operational, it will support commercial-scale production across multiple customer programs.

Christian Seufert, Head of Advanced Synthesis at Lonza, said the investments are intended to give customers greater confidence that manufacturing capacity can keep pace as their bioconjugate programs progress toward market launch. The company aims to strengthen its position as a partner for integrated bioconjugation development and manufacturing.

By combining flexible mid-scale production with additional commercial capacity, Lonza expects to provide a more scalable manufacturing pathway for ADC developers. The integrated offering is designed to simplify the transition from clinical supply to larger-scale production, improve manufacturing flexibility, and help customers maintain reliable supply as demand grows.

The expansion builds on Lonza’s previously announced investment in large-scale bioconjugation manufacturing at Visp. Together, the projects will broaden the site’s capabilities and provide additional capacity for the development and commercial production of complex bioconjugated therapies.

For more information, visit www.lonza.com.